Resistance mutation info of target

Target General Information
Target ID T58454
Target Name Fibroblast growth factor receptor 2 (FGFR2) Target Info
Gene Name FGFR2
Species Homo sapiens
Uniprot ID FGFR2_HUMAN
Sequence MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV
RCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF
MVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP
AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI
NHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK
YGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL
PAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK
RIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK
LTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM
IGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF
KDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT
TNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH
RMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS
PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT [Homo sapiens]
Drug Resistance Mutation and Corresponding Drugs
Ref 1572600Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Mutation Info Missense: E566G
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Mutation Info Missense: I548V
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Mutation Info Missense: K660E
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Mutation Info Missense: L618M
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Mutation Info Missense: M536I
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Mutation Info Missense: M538I
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Mutation Info Missense: V565I
Drugs
Drug Name Dovitinib Drug Info [555960]
Targeted Disease Endometrium Cancer
Reference
Ref 555960The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. 2013 Aug;15(8):975-88.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.